found that resveratrol exerts renoprotective effects via its radical scavenging and antioxidant activities, which appear to involve the inhibition of tissue neutrophil infiltration ( Resveratrol can act on the TGF- pathway through multiple targets and subsequently attenuate renal injury and fibrosis
Some studies have reported better preservation of renal function with SGLT2i than with GLP-1RA [19,20,21], while others have reported similar kidney outcomes with either drug class [22, 23]
GLP-1 RAs Hold Promising Potential for Reduction of Cardiometabolic Risk Factors additional benefits : Brain: Appetite suppression, nerve protection, and decreased neuroinflammation Heart: Decreased blood pressure (systolic and diastolic), reduced total cholesterol levels, lowered endothelial dysfunction, and increased heart rate Liver: Decreased glucose production Pancreas: Increased insulin secretion, decreased glucagon secretion, B islet cell proliferation GI Tract: Decreased gastric emptying Because these drugs cause weight loss, it is not clear whether the GLP-1 RAs or the weight loss reduces cardiometabolic risks
Combining KLOW with Other Research Compounds Many researchers explore KLOW blend peptide alongside other compounds to investigate synergistic effects
A clinical and neurophysiologic study]
